FdaApplication

NDA 021301

Back to search

Identifiers

Properties

PropertyValue
applicant_nameKING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC
application_typeNDA
approval_date2001-05-25

Products (12)

ProductActive ingredientStrengthDosage form
LEVOXYLLEVOTHYROXINE SODIUM0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET;ORAL
LEVOXYLLEVOTHYROXINE SODIUM0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET;ORAL
LEVOXYLLEVOTHYROXINE SODIUM0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET;ORAL
LEVOXYLLEVOTHYROXINE SODIUM0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET;ORAL
LEVOXYLLEVOTHYROXINE SODIUM0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET;ORAL
LEVOXYLLEVOTHYROXINE SODIUM0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET;ORAL
LEVOXYLLEVOTHYROXINE SODIUM0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET;ORAL
LEVOXYLLEVOTHYROXINE SODIUM0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET;ORAL
LEVOXYLLEVOTHYROXINE SODIUM0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET;ORAL
LEVOXYLLEVOTHYROXINE SODIUM0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET;ORAL
LEVOXYLLEVOTHYROXINE SODIUM0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET;ORAL
LEVOXYLLEVOTHYROXINE SODIUM0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET;ORAL

12 products